Cargando…
An in vivo study of Hypericum perforatum in a niosomal topical drug delivery system
The active compounds present in Hypericum perforatum L. (Hypericaceae) include hyperforin, hypericins and flavonoids, which are assumed to be responsible for the activity of the extract in the treatment of wounds and scars. The present study aimed to incorporate H. perforatum extract standardized to...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058565/ https://www.ncbi.nlm.nih.gov/pubmed/29382233 http://dx.doi.org/10.1080/10717544.2018.1431977 |
_version_ | 1783341724058255360 |
---|---|
author | Ali, Mohamed Abdel Motaal, Amira Ahmed, Mohammed A. Alsayari, Abdulrhman El-Gazayerly, Omaima N. |
author_facet | Ali, Mohamed Abdel Motaal, Amira Ahmed, Mohammed A. Alsayari, Abdulrhman El-Gazayerly, Omaima N. |
author_sort | Ali, Mohamed |
collection | PubMed |
description | The active compounds present in Hypericum perforatum L. (Hypericaceae) include hyperforin, hypericins and flavonoids, which are assumed to be responsible for the activity of the extract in the treatment of wounds and scars. The present study aimed to incorporate H. perforatum extract standardized to a known content of phloroglucinols, naphthodianthrones and polyphenolic compounds into an effective transdermal drug delivery system capable of entrapping both lipophilic and hydrophilic constituents in the form of niosomal gels for wound treatment. An 80% ethanol extract (HE) was prepared on a pilot scale using DIG-MAZ. An HPLC-DAD holistic profile was established for HE and was standardized to contain 3.4 ± 4 rutin, 1.1 ± 3 chlorogenic acid, 0.5 ± 2 quercitrin, 2.8 ± 2 hyperforin, and 0.51 ± 3% w/w total hypericins. Niosomes were prepared using the modified reverse phase evaporation technique (REV). The wound healing effect of the gel was tested on 16 adult mongrel dogs. A significant decrease in the inflammatory cell count (18.4 ± 5.3) was recorded in the niosomal gel 1.5% NaCMC-treated group at the 7th day post wounding. It induced a marked regression in the inflammatory phase and enhanced the early beginning of the proliferative phase of wound healing. After 21 days, it showed complete re-epithelization, formation of new matrix fibers and significant reduction in the wound size, compared to the control and the Panthenol® 2% cream treated groups. This is the first study of H. perforatum in a niosomal topical drug delivery system. |
format | Online Article Text |
id | pubmed-6058565 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-60585652018-08-17 An in vivo study of Hypericum perforatum in a niosomal topical drug delivery system Ali, Mohamed Abdel Motaal, Amira Ahmed, Mohammed A. Alsayari, Abdulrhman El-Gazayerly, Omaima N. Drug Deliv Research Article The active compounds present in Hypericum perforatum L. (Hypericaceae) include hyperforin, hypericins and flavonoids, which are assumed to be responsible for the activity of the extract in the treatment of wounds and scars. The present study aimed to incorporate H. perforatum extract standardized to a known content of phloroglucinols, naphthodianthrones and polyphenolic compounds into an effective transdermal drug delivery system capable of entrapping both lipophilic and hydrophilic constituents in the form of niosomal gels for wound treatment. An 80% ethanol extract (HE) was prepared on a pilot scale using DIG-MAZ. An HPLC-DAD holistic profile was established for HE and was standardized to contain 3.4 ± 4 rutin, 1.1 ± 3 chlorogenic acid, 0.5 ± 2 quercitrin, 2.8 ± 2 hyperforin, and 0.51 ± 3% w/w total hypericins. Niosomes were prepared using the modified reverse phase evaporation technique (REV). The wound healing effect of the gel was tested on 16 adult mongrel dogs. A significant decrease in the inflammatory cell count (18.4 ± 5.3) was recorded in the niosomal gel 1.5% NaCMC-treated group at the 7th day post wounding. It induced a marked regression in the inflammatory phase and enhanced the early beginning of the proliferative phase of wound healing. After 21 days, it showed complete re-epithelization, formation of new matrix fibers and significant reduction in the wound size, compared to the control and the Panthenol® 2% cream treated groups. This is the first study of H. perforatum in a niosomal topical drug delivery system. Taylor & Francis 2018-01-31 /pmc/articles/PMC6058565/ /pubmed/29382233 http://dx.doi.org/10.1080/10717544.2018.1431977 Text en © 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Ali, Mohamed Abdel Motaal, Amira Ahmed, Mohammed A. Alsayari, Abdulrhman El-Gazayerly, Omaima N. An in vivo study of Hypericum perforatum in a niosomal topical drug delivery system |
title | An in vivo study of Hypericum perforatum in a niosomal topical drug delivery system |
title_full | An in vivo study of Hypericum perforatum in a niosomal topical drug delivery system |
title_fullStr | An in vivo study of Hypericum perforatum in a niosomal topical drug delivery system |
title_full_unstemmed | An in vivo study of Hypericum perforatum in a niosomal topical drug delivery system |
title_short | An in vivo study of Hypericum perforatum in a niosomal topical drug delivery system |
title_sort | in vivo study of hypericum perforatum in a niosomal topical drug delivery system |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058565/ https://www.ncbi.nlm.nih.gov/pubmed/29382233 http://dx.doi.org/10.1080/10717544.2018.1431977 |
work_keys_str_mv | AT alimohamed aninvivostudyofhypericumperforatuminaniosomaltopicaldrugdeliverysystem AT abdelmotaalamira aninvivostudyofhypericumperforatuminaniosomaltopicaldrugdeliverysystem AT ahmedmohammeda aninvivostudyofhypericumperforatuminaniosomaltopicaldrugdeliverysystem AT alsayariabdulrhman aninvivostudyofhypericumperforatuminaniosomaltopicaldrugdeliverysystem AT elgazayerlyomaiman aninvivostudyofhypericumperforatuminaniosomaltopicaldrugdeliverysystem AT alimohamed invivostudyofhypericumperforatuminaniosomaltopicaldrugdeliverysystem AT abdelmotaalamira invivostudyofhypericumperforatuminaniosomaltopicaldrugdeliverysystem AT ahmedmohammeda invivostudyofhypericumperforatuminaniosomaltopicaldrugdeliverysystem AT alsayariabdulrhman invivostudyofhypericumperforatuminaniosomaltopicaldrugdeliverysystem AT elgazayerlyomaiman invivostudyofhypericumperforatuminaniosomaltopicaldrugdeliverysystem |